FDA re­jects Ab­b­Vie's in­fu­sion ther­a­py for Parkin­son's, re­quests more in­fo on pump de­vice

The FDA re­ject­ed Ab­b­Vie’s 24-hour in­fu­sion ther­a­py for Parkin­son’s, say­ing it needs more in­for­ma­tion on a de­vice used to ad­min­is­ter the treat­ment be­fore it can clear it.

The Chica­go-area drug­mak­er said in a press re­lease that the com­plete re­sponse let­ter from the agency didn’t in­clude any re­quests for more ef­fi­ca­cy or safe­ty tri­als re­lat­ed to the drug, known as AB­BV-951. The com­pa­ny said it aims to “re­sub­mit the NDA as soon as pos­si­ble.”

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER